Cognition Therapeutics (CGTX) Competitors $1.26 -0.09 (-6.67%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.04 (+3.57%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. EOLS, INBX, FULC, SLDB, ATXS, KMDA, OCGN, PRTC, YMAB, and GLUEShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Evolus (EOLS), Inhibrx Biosciences (INBX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Kamada (KMDA), Ocugen (OCGN), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Evolus Inhibrx Biosciences Fulcrum Therapeutics Solid Biosciences Astria Therapeutics Kamada Ocugen PureTech Health Y-mAbs Therapeutics Monte Rosa Therapeutics Evolus (NASDAQ:EOLS) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do insiders and institutionals hold more shares of EOLS or CGTX? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 5.9% of Evolus shares are owned by company insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, EOLS or CGTX? Cognition Therapeutics has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M1.45-$50.42M-$0.98-6.10Cognition TherapeuticsN/AN/A-$33.97M-$0.67-1.88 Does the media refer more to EOLS or CGTX? In the previous week, Evolus had 3 more articles in the media than Cognition Therapeutics. MarketBeat recorded 4 mentions for Evolus and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.89 beat Evolus' score of 1.11 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Evolus Positive Cognition Therapeutics Very Positive Which has more volatility & risk, EOLS or CGTX? Evolus has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Do analysts prefer EOLS or CGTX? Evolus presently has a consensus price target of $21.25, suggesting a potential upside of 255.35%. Cognition Therapeutics has a consensus price target of $2.83, suggesting a potential upside of 124.87%. Given Evolus' higher possible upside, equities research analysts plainly believe Evolus is more favorable than Cognition Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Cognition Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is EOLS or CGTX more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -22.31%. Cognition Therapeutics' return on equity of -251.23% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.31% -759.04% -24.63% Cognition Therapeutics N/A -251.23%-130.75% SummaryCognition Therapeutics beats Evolus on 10 of the 15 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.26M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-1.8820.6375.7726.11Price / SalesN/A442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book4.069.6212.876.30Net Income-$33.97M-$52.73M$3.29B$271.03M7 Day Performance-14.29%0.64%-0.26%-0.15%1 Month Performance-60.38%6.31%3.84%6.41%1 Year Performance203.61%18.97%68.35%28.81% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics2.8114 of 5 stars$1.26-6.7%$2.83+124.9%+176.5%$99.26MN/A-1.8820EOLSEvolus4.0057 of 5 stars$6.31+0.3%$21.25+236.8%-61.4%$406.87M$266.27M-6.44170INBXInhibrx Biosciences1.0542 of 5 stars$27.12-1.7%N/A+91.6%$399.80M$200K-2.56166Positive NewsFULCFulcrum Therapeutics1.7314 of 5 stars$7.45+0.8%$9.60+28.9%+157.0%$399.74M$80M-6.11100Positive NewsSLDBSolid Biosciences2.8266 of 5 stars$5.17+1.0%$15.00+190.1%-18.8%$398.69M$8.09M-1.85100ATXSAstria Therapeutics2.9156 of 5 stars$7.51+6.5%$30.20+302.1%-41.8%$397.87MN/A-3.7430Positive NewsKMDAKamada4.4652 of 5 stars$6.99+1.2%$13.00+86.0%+28.5%$397.36M$160.95M20.56360Positive NewsOCGNOcugen1.4184 of 5 stars$1.39+3.7%$6.00+331.7%+68.0%$391.69M$4.05M-6.9580PRTCPureTech Health0.6839 of 5 stars$16.81+3.7%N/A-11.1%$391.53M$4.83M0.00100Positive NewsGap UpYMABY-mAbs Therapeutics1.5413 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150GLUEMonte Rosa Therapeutics2.4372 of 5 stars$6.53+3.2%$15.33+134.8%+16.3%$390.94M$75.62M18.1490 Related Companies and Tools Related Companies Evolus Competitors Inhibrx Biosciences Competitors Fulcrum Therapeutics Competitors Solid Biosciences Competitors Astria Therapeutics Competitors Kamada Competitors Ocugen Competitors PureTech Health Competitors Y-mAbs Therapeutics Competitors Monte Rosa Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGTX Stock Alerts